Actinium 225 PSMA Radioligand Therapy for Prostate Cancer - 1 cycle | Theranostics Centre Vienna, Austria

The main principle of Actinium-225 therapy is a point effect on prostate tumors and metastases. Cancer cells have many receptors for a particular protein — prostate-specific membrane antigen (PSMA) on their surface. The radioactive substance (Ac-225) attaches to the PSMA molecule, which is found on prostate cancer cells. When it approaches the cancer cell, Actinium decays into alpha particles. They irradiate a cancer cell, tear its DNA, and kill it. At the same time, there is no harmful effect on neighboring healthy cells due to the short range of alpha radiation (0. 04 mm). Before therapy begins, the patient undergoes a diagnostic evaluation. It includes a PSA test, PET-CT with gallium-68, and kidney and liver function assessment. The tests help the doctor to detect metastases and assess all the risks. The drug is injected intravenously for several minutes. Actinium-225 spreads throughout the body via the bloodstream and accumulates in cancer cells. The distribution of the radionuclide is controlled by scintigraphy. The Theranosticum Vienna, under the guidance of Univ. -Prof. Dr. Marcus Hacker, Univ. -Prof. Dr. Werner Langsteger, and Univ. -Prof. Mag. Markus Mitterhauser, specializes in nuclear medicine diagnostics and outpatient personalized therapies for various types of cancer. They are located at the Institute for Nuclear Medicine and Isotope Diagnostics at the Döbling Ambulatory and Vienna General Hospital for inpatient stays. The THERANOSTICS principle, we treat what we see, means that what was previously visible is treated. This principle enables a personalized decision regarding radioligand therapy, made exclusively in close coordination between the treating physician and the patient. Together, a suitable radiopharmaceutical is selected that binds selectively and with high precision to the surfaces of tumor cells, thereby specifically destroying tumors and metastases while minimizing damage to surrounding healthy tissue. With this innovative therapy, tumor cells can be specifically targeted while sparing healthy tissue. A therapy session and observation in a hospital take only a few days. After that, the patient returns to his daily life.